Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatment burden in Progressive Pulmonary Disease and Malabsorption Syndromes.
We are dedicated to improving the lives of patients and caregivers by providing novel treatments that can be easily incorporated into their lives with the goal of making a profound improvement in their condition.
Learn more about SNSP113 and SNSP003 on our Product Development page.
At Synspira, we are inspired by patients and are driven to make a difference.